347 related articles for article (PubMed ID: 19234140)
1. Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia.
Chen R; Wierda WG; Chubb S; Hawtin RE; Fox JA; Keating MJ; Gandhi V; Plunkett W
Blood; 2009 May; 113(19):4637-45. PubMed ID: 19234140
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of NF-κB-mediated signaling by the cyclin-dependent kinase inhibitor CR8 overcomes prosurvival stimuli to induce apoptosis in chronic lymphocytic leukemia cells.
Cosimo E; McCaig AM; Carter-Brzezinski LJ; Wheadon H; Leach MT; Le Ster K; Berthou C; Durieu E; Oumata N; Galons H; Meijer L; Michie AM
Clin Cancer Res; 2013 May; 19(9):2393-405. PubMed ID: 23532892
[TBL] [Abstract][Full Text] [Related]
3. Transcription inhibition by flavopiridol: mechanism of chronic lymphocytic leukemia cell death.
Chen R; Keating MJ; Gandhi V; Plunkett W
Blood; 2005 Oct; 106(7):2513-9. PubMed ID: 15972445
[TBL] [Abstract][Full Text] [Related]
4. Mechanism and functional role of XIAP and Mcl-1 down-regulation in flavopiridol/vorinostat antileukemic interactions.
Rosato RR; Almenara JA; Kolla SS; Maggio SC; Coe S; Giménez MS; Dent P; Grant S
Mol Cancer Ther; 2007 Feb; 6(2):692-702. PubMed ID: 17308065
[TBL] [Abstract][Full Text] [Related]
5. The cyclin-dependent kinase inhibitor SNS-032 induces apoptosis in breast cancer cells via depletion of Mcl-1 and X-linked inhibitor of apoptosis protein and displays antitumor activity in vivo.
Xie G; Tang H; Wu S; Chen J; Liu J; Liao C
Int J Oncol; 2014 Aug; 45(2):804-12. PubMed ID: 24865236
[TBL] [Abstract][Full Text] [Related]
6. Cyclin-dependent kinase 9 activity regulates neutrophil spontaneous apoptosis.
Wang K; Hampson P; Hazeldine J; Krystof V; Strnad M; Pechan P; M J
PLoS One; 2012; 7(1):e30128. PubMed ID: 22276149
[TBL] [Abstract][Full Text] [Related]
7. Responses in mantle cell lymphoma cells to SNS-032 depend on the biological context of each cell line.
Chen R; Chubb S; Cheng T; Hawtin RE; Gandhi V; Plunkett W
Cancer Res; 2010 Aug; 70(16):6587-97. PubMed ID: 20663900
[TBL] [Abstract][Full Text] [Related]
8. Seliciclib (CYC202, R-Roscovitine) induces cell death in multiple myeloma cells by inhibition of RNA polymerase II-dependent transcription and down-regulation of Mcl-1.
MacCallum DE; Melville J; Frame S; Watt K; Anderson S; Gianella-Borradori A; Lane DP; Green SR
Cancer Res; 2005 Jun; 65(12):5399-407. PubMed ID: 15958589
[TBL] [Abstract][Full Text] [Related]
9. Homoharringtonine reduced Mcl-1 expression and induced apoptosis in chronic lymphocytic leukemia.
Chen R; Guo L; Chen Y; Jiang Y; Wierda WG; Plunkett W
Blood; 2011 Jan; 117(1):156-64. PubMed ID: 20971952
[TBL] [Abstract][Full Text] [Related]
10. Pim kinase inhibitor, SGI-1776, induces apoptosis in chronic lymphocytic leukemia cells.
Chen LS; Redkar S; Bearss D; Wierda WG; Gandhi V
Blood; 2009 Nov; 114(19):4150-7. PubMed ID: 19734450
[TBL] [Abstract][Full Text] [Related]
11. The CDK inhibitor, R-roscovitine, promotes eosinophil apoptosis by down-regulation of Mcl-1.
Duffin R; Leitch AE; Sheldrake TA; Hallett JM; Meyer C; Fox S; Alessandri AL; Martin MC; Brady HJ; Teixeira MM; Dransfield I; Haslett C; Rossi AG
FEBS Lett; 2009 Aug; 583(15):2540-6. PubMed ID: 19616548
[TBL] [Abstract][Full Text] [Related]
12. Up-regulation of CDK9 kinase activity and Mcl-1 stability contributes to the acquired resistance to cyclin-dependent kinase inhibitors in leukemia.
Yeh YY; Chen R; Hessler J; Mahoney E; Lehman AM; Heerema NA; Grever MR; Plunkett W; Byrd JC; Johnson AJ
Oncotarget; 2015 Feb; 6(5):2667-79. PubMed ID: 25596730
[TBL] [Abstract][Full Text] [Related]
13. SNS-032 is a potent and selective CDK 2, 7 and 9 inhibitor that drives target modulation in patient samples.
Conroy A; Stockett DE; Walker D; Arkin MR; Hoch U; Fox JA; Hawtin RE
Cancer Chemother Pharmacol; 2009 Sep; 64(4):723-32. PubMed ID: 19169685
[TBL] [Abstract][Full Text] [Related]
14. The cyclin-dependent kinase inhibitor SNS-032 has single agent activity in AML cells and is highly synergistic with cytarabine.
Walsby E; Lazenby M; Pepper C; Burnett AK
Leukemia; 2011 Mar; 25(3):411-9. PubMed ID: 21212792
[TBL] [Abstract][Full Text] [Related]
15. Phase I and pharmacologic study of SNS-032, a potent and selective Cdk2, 7, and 9 inhibitor, in patients with advanced chronic lymphocytic leukemia and multiple myeloma.
Tong WG; Chen R; Plunkett W; Siegel D; Sinha R; Harvey RD; Badros AZ; Popplewell L; Coutre S; Fox JA; Mahadocon K; Chen T; Kegley P; Hoch U; Wierda WG
J Clin Oncol; 2010 Jun; 28(18):3015-22. PubMed ID: 20479412
[TBL] [Abstract][Full Text] [Related]
16. Cyclin-dependent kinase inhibitor Roscovitine induces apoptosis in chronic lymphocytic leukemia cells.
Hahntow IN; Schneller F; Oelsner M; Weick K; Ringshausen I; Fend F; Peschel C; Decker T
Leukemia; 2004 Apr; 18(4):747-55. PubMed ID: 14973497
[TBL] [Abstract][Full Text] [Related]
17. Transcriptional inhibition by CDK7/9 inhibitor SNS-032 suppresses tumor growth and metastasis in esophageal squamous cell carcinoma.
Zeng H; Yang H; Song Y; Fang D; Chen L; Zhao Z; Wang C; Xie S
Cell Death Dis; 2021 Nov; 12(11):1048. PubMed ID: 34741018
[TBL] [Abstract][Full Text] [Related]
18. Cyclin-dependent kinase 7/9 inhibitor SNS-032 abrogates FIP1-like-1 platelet-derived growth factor receptor α and bcr-abl oncogene addiction in malignant hematologic cells.
Wu Y; Chen C; Sun X; Shi X; Jin B; Ding K; Yeung SC; Pan J
Clin Cancer Res; 2012 Apr; 18(7):1966-78. PubMed ID: 22447844
[TBL] [Abstract][Full Text] [Related]
19. The lethal effects of pharmacological cyclin-dependent kinase inhibitors in human leukemia cells proceed through a phosphatidylinositol 3-kinase/Akt-dependent process.
Yu C; Rahmani M; Dai Y; Conrad D; Krystal G; Dent P; Grant S
Cancer Res; 2003 Apr; 63(8):1822-33. PubMed ID: 12702569
[TBL] [Abstract][Full Text] [Related]
20. Transient treatment with CDK inhibitors eliminates proliferative potential even when their abilities to evoke apoptosis and DNA damage are blocked.
Scrace SF; Kierstan P; Borgognoni J; Wang LZ; Denny S; Wayne J; Bentley C; Cansfield AD; Jackson PS; Lockie AM; Curtin NJ; Newell DR; Williamson DS; Moore JD
Cell Cycle; 2008 Dec; 7(24):3898-907. PubMed ID: 19066469
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
